Long‐Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver‐Related Outcomes
Open Access
- 7 March 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 72 (4), 1177-1190
- https://doi.org/10.1002/hep.31214
Abstract
Background & aims Hepatitis delta virus (HDV) infection is associated with fast progression to liver cirrhosis and liver complications. Previous studies have though been mainly from tertiary care centers, with risk for referral bias towards patients with worse outcomes. Furthermore, the impact of HDV viremia per se on liver‐related outcomes is not really known outside HIV co‐infection setting. We have therefore evaluated the long‐term impact of HDV viremia on liver‐related outcomes in a nationwide cohort of hepatitis B and D co‐infected patients, cared for at secondary care centers in Sweden. Approach & Results In total 337 anti‐HDV positive patients including 233 patients with HDV RNA viremia and 91 without HDV viremia at baseline were retrospectively studied, with a mean follow‐up of 6.5 years (range 0.5‐33.1). The long‐term risks for liver‐related events (i.e. hepatocellular carcinoma [HCC], hepatic decompensation, or liver‐related death/transplantation) were assessed, using Cox regression analysis. The risk for liver‐related events and HCC was 3.8 and 2.6 fold higher, respectively, in patients with HDV viremia compared to those without viremia, although the latter was not statistically significant. Among HDV viremic patients with no baseline cirrhosis, the cumulative risk of being free of liver cirrhosis or liver‐related events was 81.9% and 64.0%, after 5 and 10 years of follow‐up, respectively. This corresponds to an incidence rate of 0.04 per person‐year. Conclusion HDV RNA viremia is associated with a 3.8 fold higher risk for liver‐related outcomes. The prognosis was rather poor for non‐cirrhotic patients with HDV viremia at baseline, but it was nevertheless more benign than previous estimates from tertiary centers. Our findings can be of importance when treatment decision making, and evaluating outcomes of upcoming new antivirals against HDV.Keywords
Funding Information
- Gilead Sciences (Nordic fellowship)
This publication has 32 references indexed in Scilit:
- Hepatitis Delta and HIV InfectionSeminars in Liver Disease, 2012
- EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinomaEuropean Journal Of Cancer, 2012
- Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up studyJournal of Viral Hepatitis, 2011
- Retrospective Analysis of Chronic Hepatitis D in a West German University Clinic over Two Decades: Migratory Pattern, Prevalence and Clinical OutcomeZeitschrift für Gastroenterologie, 2010
- Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-AnalysisGastroenterology, 2008
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionHepatology, 2006
- Long-term benefit of interferon α therapy of chronic hepatitis D: regression of advanced hepatic fibrosisGastroenterology, 2004
- Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type BGut, 2000
- Risk of liver cirrhosis and hepatocellular carcinoma in subjects with hepatitis B and delta virus infection: A study from Kure, JapanJournal of Gastroenterology and Hepatology, 1993
- Hepatitis D Virus and Human Immunodeficiency Virus Antibodies in Parenteral Drug Abusers Who Are Hepatitis B Surface Antigen PositiveThe Journal of Infectious Diseases, 1988